New hope for stomach cancer patients: drug combo tested before and after surgery
NCT ID NCT04882241
Summary
This study tested whether adding the immunotherapy drug pembrolizumab to standard chemotherapy improves outcomes for Chinese adults with stomach or gastroesophageal junction cancer. The treatment was given both before surgery (to shrink tumors) and after surgery (to prevent recurrence). Researchers compared the drug combination against chemotherapy plus a placebo in 120 participants to see if it helped patients live longer without their cancer returning.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Afflilated Hospital of Bengbu Medical College-Surgical Oncology (Site 0638)
Bengbu, Anhui, 233004, China
-
Beijing Cancer Hospital ( Site 0221)
Beijing, Beijing Municipality, 100142, China
-
Beijing Friendship Hospital ( Site 0637)
Beijing, Beijing Municipality, 100050, China
-
Fourth Hospital of Hebei Medical University ( Site 0633)
Shijiazhuang, Hebei, 050035, China
-
Fujian Medical University Union Hospital-1 Bingfanglou-Gastric Surgery Department (Site 0632)
Fuzhou Fujian, Fujian, 350001, China
-
Fujian Provincial Cancer Hospital ( Site 0230)
Fuzhou, Fujian, 350014, China
-
Henan Cancer Hospital (Site 0227)
Zhengzhou, Henan, 450008, China
-
Renji Hospital Shanghai Jiao Tong University School of Medicine ( Site 0642)
Shanghai, Shanghai Municipality, 200127, China
-
Shandong Provincial Hospital-Gastrointestinal Surgery ( Site 0640)
Jinan, Shandong, 250001, China
-
Sichuan Cancer hospital
Chengdu, Sichuan, 610041, China
-
Sir Run Run Shaw Hospital ( Site 0233)
Hangzhou, Zhejiang, 430030, China
-
Tangdu Hospital of Fourth Military Medical University of Chinese People's Liberation Army ( Site 0647)
Xi'an, Shaanxi, 710038, China
-
The Affiliated Hospital of Qingdao University ( Site 0636)
Qingdao, Shandong, 266003, China
-
The Affiliated Hospital of Xuzhou Medical College-Oncology ( Site 0645)
Xuzhou, Jiangsu, 221006, China
-
The First Affiliated Hospital of Guangzhou Medical University ( Site 0224)
Guangzhou, Guangdong, 510120, China
-
The First Affiliated Hospital of Wenzhou Medical University (Site 0652)
Wenzhou, Zhejiang, 32500, China
-
The First Affiliated Hospital, Sun Yat-sen University (Site 0635)
Guangzhou, Guangdong, 510080, China
-
The First Hospital of Jilin University-Gastrointestinal Surgery ( Site 0234)
Changchun, Jilin, 130021, China
-
Zhejiang Cancer Hospital ( Site 0231)
Hangzhou, Zhejiang, 310022, China
-
Zhejiang Provincial People's Hospital-Oncology (Site 0656)
Hangzhou, Zhejiang, 310014, China
Conditions
Explore the condition pages connected to this study.